HENLIUS (02696.HK) has reported a robust financial performance for the first half of fiscal year 2026, marked by simultaneous growth in both revenue and net profit. During the reporting period, the company achieved a total revenue of RMB 3.588 billion, representing a 27.3% increase year-over-year. Net profit attributable to shareholders climbed to RMB 430.4 million, up 10.3% compared to the same period last year.
Further highlighting its operational strength, the company's non-IFRS profit for the first half of 2026 reached RMB 572.3 million, reflecting a substantial 46.7% surge from the prior year. The company also reported a Non-IFRS adjusted EBITDA of RMB 904.1 million for the period, a 35.2% jump year-over-year, underscoring improved underlying profitability and efficiency.
In a significant corporate development, HENLIUS also announced its inclusion as a constituent stock of the Hang Seng Composite Index. This selection was based on the quarterly index review results released by Hang Seng Indexes Company Limited on August 21, 2026, with data as of June 30, 2026. The new index membership is scheduled to become effective on September 7, 2026.
Commenting on the results and the company's strategic direction, Mr. Zhu Jun, Executive Director and Chief Executive Officer of HENLIUS, stated that 2026 represents a pivotal acceleration year for the company's transition towards becoming a C-MNC (China-based Multinational Corporation). During the first half of the year, the company's core products continued to deliver tangible value through global commercialization efforts. Concurrently, its differentiated innovative pipeline has entered a critical phase of value validation, with the dual-engine growth strategy starting to yield visible results. Looking ahead, Mr. Zhu emphasized that the company will remain firmly anchored on addressing patients' unmet clinical needs while comprehensively deepening its Globalization 2.0 strategic framework.
Comments